Amanda L. Hudson
YOU?
Author Swipe
View article: PATH-52. Understanding the prevalence of <i>MTAP</i> and <i>CDKN2A/B</i> deletion in gliomas by next generation sequencing
PATH-52. Understanding the prevalence of <i>MTAP</i> and <i>CDKN2A/B</i> deletion in gliomas by next generation sequencing Open
BACKGROUND CDKN2A/B (cyclin-dependent kinase inhibitor 2A/B) gene alterations are integral to the diagnosis and prognostication of IDH-mutant gliomas. CDKN2A/B status is commonly assessed by next generation sequencing (NGS) or inferred fro…
View article: Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours
Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours Open
This study demonstrates that glioma patients can mount meaningful immune responses to DNA and mRNA vaccines, suggesting that glioma-based vaccine therapies are feasible and warrant further exploration.
View article: COVID-19 vaccinations in COVID-19 naïve population to predict utility of tumour-based vaccinations in glioma patients
COVID-19 vaccinations in COVID-19 naïve population to predict utility of tumour-based vaccinations in glioma patients Open
Background Gliomas are the most common primary brain malignancy in adults, with treatment advances limited by challenges like the blood-brain barrier, tumour heterogeneity, and an immunosuppressive microenvironment. Tumour vaccines, such a…
View article: Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination
Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination Open
Solid tumor malignancy (STM) patients experience increased risk of breakthrough SARS-CoV-2 infection owing to reduced COVID-19 vaccine immunogenicity. However, the underlying immunological causes of impaired neutralization remain poorly ch…
View article: Clinical outcomes and management of <i>CDKN2A/B</i> homozygously deleted IDH-mutant astrocytomas—a cohort study and patterns of care survey
Clinical outcomes and management of <i>CDKN2A/B</i> homozygously deleted IDH-mutant astrocytomas—a cohort study and patterns of care survey Open
Background The use of CDKN2A/B deletions in the current WHO CNS classification (5th edition, 2021), has led to some ambiguity in patient management. Further clinical studies are required to fully ascertain the clinical impact of CDKN2A/B d…
View article: A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions – a retrospective cohort review
A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions – a retrospective cohort review Open
Hypersensitivity reactions (HSRs) limit cetuximab use in KRAS wildtype advanced colorectal cancer, with a significant driver being pre-formed IgE antibodies against galactose-1,3-alpha-galactose (alpha-gal). Our multicentric retrospective …
View article: CA9, CYFIP2 and LGALS3BP—A Novel Biomarker Panel to Aid Prognostication in Glioma
CA9, CYFIP2 and LGALS3BP—A Novel Biomarker Panel to Aid Prognostication in Glioma Open
Brain cancer is a devastating and life-changing disease. Biomarkers are becoming increasingly important in addressing clinical issues, including in monitoring tumour progression and assessing survival and treatment response. The goal of th…
View article: CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review
CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review Open
Genomic alterations of CDKN2A and CDKN2B in astrocytomas have been an evolving area of study for decades. Most recently, there has been considerable interest in the effect of CDKN2A and/or CDKN2B (CDKN2A/B) homozygous deletions (HD) on the…
View article: PSMA Expression Correlates with Improved Overall Survival and VEGF Expression in Glioblastoma
PSMA Expression Correlates with Improved Overall Survival and VEGF Expression in Glioblastoma Open
Background: Glioblastomas are the most common and fatal primary brain malignancy in adults. There is a growing interest in identifying the molecular mechanisms of these tumors to develop novel treatments. Glioblastoma neo-angiogenesis is d…
View article: Supplementary Figures 1 - 6 from Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines
Supplementary Figures 1 - 6 from Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines Open
PDF file - 263K, SI Figure 1: Tumor growth in rats treated with non-reduced tumor lysate versus control (Adjuvant only) in two separate experiments. SI Figure 2 : Interferon- and IL-4 levels in control and vaccine treated rats 21 days post…
View article: Supplementary Figures 1 - 6 from Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines
Supplementary Figures 1 - 6 from Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines Open
PDF file - 263K, SI Figure 1: Tumor growth in rats treated with non-reduced tumor lysate versus control (Adjuvant only) in two separate experiments. SI Figure 2 : Interferon- and IL-4 levels in control and vaccine treated rats 21 days post…
View article: Data from Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines
Data from Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines Open
Induction of antitumor immunity using autologous tumor proteins is an attractive approach to cancer therapy. However, better methods and stimulants to present these autologous proteins back to the immune system are needed. Here, we identif…
View article: Data from Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines
Data from Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines Open
Induction of antitumor immunity using autologous tumor proteins is an attractive approach to cancer therapy. However, better methods and stimulants to present these autologous proteins back to the immune system are needed. Here, we identif…
View article: The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer
The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer Open
Pancreatic cancer has poor survival despite modern-day advances in its management. At present, there are no available biomarkers that can predict chemotherapy response or help inform prognosis. In more recent years, there has been increase…
View article: An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma
An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma Open
Mesothelioma is an aggressive cancer with limited treatment options and a poor prognosis. Phytocannabinoids possess anti-tumour and palliative properties in multiple cancers, however their effects in mesothelioma are unknown. We investigat…
View article: 0119 Effects of Total Sleep Deprivation on Performance on a Continuous Performance Matching Task
0119 Effects of Total Sleep Deprivation on Performance on a Continuous Performance Matching Task Open
Introduction Tasks requiring individuals to identify specific stimuli may create response/non-response conflict, which may impair performance depending on stimulus feature overlap. Whether sleep deprivation interacts with such impairment i…
View article: Additional file 2 of Differential effects of radiation fractionation regimens on glioblastoma
Additional file 2 of Differential effects of radiation fractionation regimens on glioblastoma Open
Additional file 2. Table S2: Fluorescent band intensity for western blots.
View article: Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer
Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer Open
Tyrosine kinase inhibitors (TKIs) are the first-line therapy for non-small-cell lung cancers (NSCLC) that harbour sensitising mutations within the epidermal growth factor receptor (EGFR). However, resistance remains a key issue, with tumou…
View article: Are In Vitro Human Blood–Brain–Tumor-Barriers Suitable Replacements for In Vivo Models of Brain Permeability for Novel Therapeutics?
Are In Vitro Human Blood–Brain–Tumor-Barriers Suitable Replacements for In Vivo Models of Brain Permeability for Novel Therapeutics? Open
Background: High grade gliomas (HGG) are incapacitating and prematurely fatal diseases. To overcome the poor prognosis, novel therapies must overcome the selective and restricted permeability of the blood–brain barrier (BBB). This study cr…
View article: <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling
<i>ALK</i>-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling Open
Since its discovery in 2007, we have seen the lives of patients diagnosed with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancers (NSCLC) transform with the advent of molecular therapies with first-, second-, …
View article: Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model
Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model Open
Glioblastoma, the most aggressive form of glioma, has a 5-year survival rate of <5%. While radiation and immunotherapies are routinely studied in the murine Gl261 glioma model, little is known about its inherent immune response. This study…
View article: Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer
Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer Open
Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immu…
View article: Molecular and clonal evolution in recurrent metastatic gliosarcoma
Molecular and clonal evolution in recurrent metastatic gliosarcoma Open
We discuss the molecular evolution of gliosarcoma, a mesenchymal type of glioblastoma (GBM), using the case of a 37-yr-old woman who developed two recurrences and an extracranial metastasis. She was initially diagnosed with isocitrate dehy…
View article: Temporal and spatial modulation of the immune response of the murine Gl261 glioma tumor microenvironment
Temporal and spatial modulation of the immune response of the murine Gl261 glioma tumor microenvironment Open
Glioblastoma, the most aggressive form of glioma, has a 5-year survival rate of <5%. While radiation and immunotherapies are routinely studied in the murine Gl261 glioma model, little is known about its inherent immune response. This study…
View article: IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT
IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT Open
INTRODUCTION Glioma is a debilitating and early fatal cancer arising in the glial cells of brain. Glioblastoma, the most aggressive form of gliomas, has a 5-year survival rate of 5% with treatment options limited to surgery, radiotherapy o…
View article: GENE-20. IDENTIFYING POTENTIAL GENES AND MECHANISMS DRIVING IDH-MUTANT GLIOMA PROGRESSION AND RECURRENCE THROUGH RNA-SEQUENCING
GENE-20. IDENTIFYING POTENTIAL GENES AND MECHANISMS DRIVING IDH-MUTANT GLIOMA PROGRESSION AND RECURRENCE THROUGH RNA-SEQUENCING Open
Gliomas are the most common primary brain tumors in adults. IDH-mutated low-grade gliomas of astrocytic lineage (astrocytomas) have a relatively indolent clinical course; however, over time they progress to a higher grade. Molecular studie…